CSL Seqirus (CSL)

Executive Summary

CSL Seqirus, a business unit of CSL Limited, is one of the world’s largest influenza vaccine providers, operating state-of-the-art manufacturing facilities across three continents. The company plays a critical role in seasonal flu prevention and global pandemic preparedness, leveraging its differentiated cell-based and adjuvanted vaccine technologies. With a portfolio including Flucelvax® Quadrivalent (cell-based) and Afluria® Quadrivalent (egg-based), Seqirus has established a resilient supply chain and a strong presence in both public and private markets. The company continues to invest in expanding its capacity and pipeline, including next-generation vaccines and pandemic response platforms. Recent partnerships with governments and global health organizations underscore its strategic importance in mitigating the impact of annual flu epidemics and potential pandemic threats. As of mid-2026, Seqirus benefits from robust demand for flu vaccines and ongoing revenue contributions from its seasonal and pandemic product lines. The business is poised to capture growth through innovation and global expansion, reinforced by CSL’s broader capabilities in biologics and specialty therapies.

Upcoming Catalysts (preview)

• Q3 2026Award of a major H5N1 pandemic preparedness contract from the U.S. government or other national health authorities, potentially boosting revenue and visibility.70% success
• Q3 2026FDA approval of Flucelvax Quadrivalent for a new pediatric age indication (e.g., down to 6 months), expanding the addressable market.60% success
• Q4 2026Completion and regulatory approval of a new manufacturing facility in the U.S. or Europe, increasing production capacity for seasonal and pandemic vaccines.75% success